Johnson & Johnson (JNJ) Q2 FY25 earnings call

Johnson & Johnson delivered a robust second quarter, showcasing the strength of its diversified Innovative Medicine and MedTech portfolios. Despite significant headwinds from STELARA's loss of exclusivity and Part D redesign, the company achieved strong operational sales growth and raised its full-year sales and EPS guidance. Management emphasized innovation and pipeline progress as key drivers for sustained growth through the end of the decade.